Skip to main content
Qualigen Therapeutics, Inc. logo

Qualigen Therapeutics, Inc. — Investor Relations & Filings

Ticker · QLGN ISIN · US74754R1032 US Professional, scientific and technical activities
Open in API
Filings indexed 618 across all filing types
Latest filing 2015-06-24 Director's Dealing
Country US United States of America
Listing US QLGN

About Qualigen Therapeutics, Inc.

https://qlgntx.com/

Qualigen Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel treatments for cancer. The company's efforts are directed toward creating therapeutics for both adult and pediatric patients, with a particular emphasis on rare cancers and areas of high unmet medical need. Its development approach combines internal capabilities with collaborations from major cancer research institutions. The company's investigational oncology pipeline includes programs such as QN-302, a Pan-RAS inhibitor platform, and QN-247.

Recent filings

Filing Released Lang Actions
3 Filing
Director's Dealing
2015-06-24 English
3 Filing
Director's Dealing
2015-06-24 English
Regulatory Filings 2015
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC Division of Corporate Finance regarding a Form S-1 registration statement for Ritter Pharmaceuticals, Inc. It requests acceleration of the effective date of the registration statement and discusses compliance with securities regulations related to the offering. The document is short (1817 characters) and is a correspondence related to a securities offering, not a financial report or detailed filing. It does not contain financial statements or detailed financial data. This type of document is best classified as a Regulatory Filing (RNS) because it is a regulatory correspondence related to a registration statement and does not fit into other specific categories like Capital/Financing Update (CAP) or Annual Report (10-K).
2015-06-22 English
Capital/Financing Update 2015
Capital/Financing Update Classification · 95% confidence The document is a letter from Ritter Pharmaceuticals, Inc. to the SEC requesting acceleration of the effective date of a Registration Statement on Form S-1. It references Rule 461 under the Securities Act of 1933 and discusses procedural aspects of the registration statement becoming effective. There is no financial data, earnings information, or report content. The document is a regulatory communication related to a capital raising process (registration statement for securities offering). This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2015-06-22 English
FREE WRITING PROSPECTUS
Capital/Financing Update Classification · 95% confidence The document is titled 'FREE WRITING PROSPECTUS' and references SEC Rule 433, which governs free writing prospectuses used in securities offerings. It includes detailed information about an initial public offering (IPO) including shares offered, expected price, company mission, clinical trial data, and investment opportunity. The document is a marketing and disclosure communication related to a securities offering, not a financial report, earnings release, or regulatory filing of financial results. It is not an Annual Report, Interim Report, or Earnings Release. It is not a Board or Management change announcement, nor a voting result or dividend notice. The document is a Free Writing Prospectus, which is a type of offering document used in capital raising. According to the filing definitions, this fits best under Capital/Financing Update (CAP) as it relates to company fundraising and securities offering information.
2015-06-19 English
AMENDMENT NO. 5 TO FORM S-1
Regulatory Filings Classification · 100% confidence The document is titled "Amendment No. 5 to Form S-1" and is a registration statement filed with the U.S. Securities and Exchange Commission (SEC) under the Securities Act of 1933. It includes detailed information about the company's securities offering, including the number of shares, offering price, underwriting details, risk factors, business description, management, and financial statements. The Form S-1 is a registration statement used for initial public offerings (IPOs) and other securities offerings. This document is not an annual report, earnings release, or any other financial report but a regulatory filing related to securities registration and offering. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2015-06-19 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.